Clinical Trial

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability and drug levels of Navlimetostat (BMS-986504) in participants with advanced solid tumors.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-07-21; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07077434
Lead Sponsor Bristol-Myers Squibb
Conditions Advanced Solid Tumors
Enrollment 32 participants
Start Date 2025-10-15
Primary Completion 2027-01-19 (estimated)
Study Completion 2027-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-03